CalciMedica and EpiPharma Enter into Research Collaboration to Discover and Develop CRAC Channel Inhibitor Therapies

Under the terms of the research collaboration agreement, CalciMedica will use EpiPharma’s state of the art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate its drug discovery pipeline La Jolla, Calif., USA; Szeged and Budapest, Hungary July 15, 2020 – CalciMedica, a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of […]

CalciMedica Announces Data Showing Auxora™ Substantially Improved Outcomes in Patients with Severe COVID-19 Pneumonia

Link to Full Article Median time to recovery was more than two times faster for patients treated with Auxora plus standard of care compared to standard of care alone The percentage of patients requiring invasive mechanical ventilation was 2.8 times lower with Auxora plus standard of care compared to standard of care alone Treating 2.6 […]

CALCIMEDICA APPOINTS ROBERT N. WILSON, FORMER J&J VICE CHAIRMAN AS CO-CHAIRMAN OF THE BOARD OF DIRECTORS AND ERIC W. ROBERTS AS VICE CHAIRMAN

Former Johnson & Johnson Vice Chairman, Robert N. Wilson, joins CalciMedica as Co-Chairman  Board Member, Eric W. Roberts, named Vice Chairman and Chairman of the Strategic Transactions and Finance Committee of the Board LA JOLLA, Calif., June 2, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels […]

CALCIMEDICA RAISES $15 MILLION IN SERIES C FINANCING ROUND LED BY VALENCE LIFE SCIENCES

Link to Full Article Funds to support ongoing clinical trials in patients with COVID-19 pneumonia and commercial manufacturing of Auxora™  LA JOLLA, Calif., May 22, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced it has […]

CALCIMEDICA ANNOUNCES THAT FDA HAS STRONGLY RECOMMENDED MOVING TO A BLINDED PLACEBO-CONTROLLED TRIAL WITH AUXORA™ IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA

LA JOLLA, Calif., May 21, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced that it has received guidance from the U.S. Food and Drug Administration (FDA) regarding the Company’s ongoing study of Auxora™ (formerly called […]